Eugene Depasquale

Dr. Eugene DePasquale is the Medical Director of the Heart Failure, Heart Transplantation and Mechanical Circulatory Support Program at the University of Southern California. Dr. DePasquale received his M.D. degree from State University of New York, Downstate College of Medicine. He completed his Internal Medicine Residency, Fellowship in Cardiovascular Medicine, and a Fellowship in Advanced Heart Failure and Transplant Cardiology at the Yale-New Haven Hospital. At the same institution, he was Chief Cardiology Fellow, and completed an additional Fellowship with a focus in Inherited Cardiomyopathies with additional study at University College London.

His research interests include heart transplantation and mechanical circulatory support outcomes, as well as studies of novel heart failure and cardiomyopathy therapies. Additional interests include noninvasive rejection surveillance as well as studies of novel heart failure and cardiomyopathy therapies, including hypertrophic cardiomyopathy.

In addition, Dr. DePasquale has a strong interest in sports cardiology serves as a medical consultant for the Women’s Tennis Association and USC Athletics. He served as a medical consultant for the US Open Tennis Championships from 2003 to 2020. Additionally, he serves on a national committee for the United States Tennis Association.

• International Society for Heart & Lung Transplantation: Transplant Registry Early Career Award, 2013

• Redefining the molecular rejection states in 3230 heart transplant biopsies: relationships to parenchymal injury and graft survival Am J Transplant. 2024 Mar 23. . View in PubMed
• Optimizing cardiac status in the preliver transplant candidate Curr Opin Organ Transplant. 2024 Feb 01; 29(1):50-55. . View in PubMed
• Molecular states associated with dysfunction and graft loss in heart transplants J Heart Lung Transplant. 2023 Nov 30. . View in PubMed
• New UNOS allocation system associated with no added benefit in waitlist outcomes and worse post-transplant survival in heart-kidney patients J Heart Lung Transplant. 2023 11; 42(11):1529-1542. . View in PubMed
• Effect of the UNOS policy change on rates of rejection, infection, and hospital readmission following heart transplantation J Heart Lung Transplant. 2023 10; 42(10):1415-1424. . View in PubMed
• The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients J Heart Lung Transplant. 2023 05; 42(5):e1-e141. . View in PubMed
• Effect of UNOS policy change and exception status request on outcomes in patients bridged to heart transplant with an intra-aortic balloon pump Artif Organs. 2022 May; 46(5):838-849. . View in PubMed
• UNOS policy change benefits high-priority patients without harming those at low priority Am J Transplant. 2022 12; 22(12):2931-2941. . View in PubMed
• Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes J Heart Lung Transplant. 2022 03; 41(3):334-344. . View in PubMed
• Two is better than one: when to consider multiorgan transplant Curr Opin Organ Transplant. 2022 02 01; 27(1):86-91. . View in PubMed
• Assessing the Relationship Between Molecular Rejection and Parenchymal Injury in Heart Transplant Biopsies Transplantation. 2022 11 01; 106(11):2205-2216. . View in PubMed
• Acute ST-Segment Elevation Myocardial Infarction as Initial Presentation of Atypical Hemolytic-Uremic Syndrome JACC Case Rep. 2021 Apr; 3(4):561-565. . View in PubMed
• Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection J Med Virol. 2021 05; 93(5):2645-2653. . View in PubMed
• Relapsing Polychondritis Requiring Orthotopic Heart Transplant Despite Coronary Artery Bypass and Surgical Aortic Valve Replacement JACC Case Rep. 2020 Aug; 2(10):1527-1531. . View in PubMed
• 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy Heart Rhythm. 2019 11; 16(11):e301-e372. . View in PubMed
• 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary Heart Rhythm. 2019 11; 16(11):e373-e407. . View in PubMed
• Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study Am J Transplant. 2019 10; 19(10):2889-2899. . View in PubMed
• An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms J Heart Lung Transplant. 2019 06; 38(6):636-646. . View in PubMed
• Temporary Venoarterial Extracorporeal Membrane Oxygenation: Ten-Year Experience at a Cardiac Transplant Center J Intensive Care Med. 2018 May; 33(5):288-295. . View in PubMed
• Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients Transplantation. 2018 10; 102(10):e431-e438. . View in PubMed
• Clinical phenomapping and outcomes after heart transplantation J Heart Lung Transplant. 2018 08; 37(8):956-966. . View in PubMed
• Heart and heart-liver transplantation in adults with failing Fontan physiology Clin Transplant. 2018 08; 32(8):e13329. . View in PubMed
• Predicting the Future of Cardiac Allograft Vasculopathy With Cardiac Positron Emission Tomography: Ready for Prime Time? Circ Heart Fail. 2018 06; 11(6):e005136.. View in PubMed
• Prognostic utility of MELD-XI in adult congenital heart disease patients undergoing cardiac transplantation Clin Transplant. 2018 06; 32(6):e13257. . View in PubMed
• Primary graft dysfunction in heart transplantation Curr Opin Organ Transplant. 2018 06; 23(3):286-294. . View in PubMed
• Exploring the cardiac response to injury in heart transplant biopsies JCI Insight. 2018 10 18; 3(20). . View in PubMed
• Cardiac Amyloidosis: Diagnosis and Treatment Strategies Curr Oncol Rep. 2017 Jul; 19(7):46. . View in PubMed
• Survival After Heart Transplantation in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy J Card Fail. 2017 Feb; 23(2):107-112. . View in PubMed
• Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy Heart Fail Rev. 2017 11; 22(6):879-888. . View in PubMed
• ISHLT Transplant Registry: Youthful Investment-The Path to Progress J Heart Lung Transplant. 2017 10; 36(10):1027-1036. . View in PubMed
• Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy J Card Fail. 2016 Jun; 22(6):439-48. . View in PubMed
• Familial dilated cardiomyopathy diagnosis is commonly overlooked at the time of transplant listing J Heart Lung Transplant. 2016 Apr; 35(4):474-80. . View in PubMed
• Socioeconomic Disparities in Heart Transplantation: A Universal Fix? Circ Cardiovasc Qual Outcomes. 2016 11; 9(6):693-694.. View in PubMed
• Team-Based Care for Outpatients with Heart Failure Heart Fail Clin. 2015 Jul; 11(3):379-405. . View in PubMed
• A contemporary review of adult heart transplantation: 2012 to 2013 J Heart Lung Transplant. 2014 Aug; 33(8):775-84. . View in PubMed
• Anomalous left coronary artery in hypertrophic cardiomyopathy Ann Thorac Surg. 2014 Jun; 97(6):2190-3. . View in PubMed
• Management of ACCF/AHA Stage C heart failure Cardiol Clin. 2014 Feb; 32(1):73-93viii. . View in PubMed
• Impact of atrial fibrillation on outcomes in heart failure Heart Fail Clin. 2013 Oct; 9(4):437-49viii. . View in PubMed
• Obesity in heart failure: impact on survival and treatment modalities Expert Rev Cardiovasc Ther. 2013 Sep; 11(9):1141-53. . View in PubMed
• Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment CMAJ. 2013 Feb 05; 185(2):127-34. . View in PubMed
• Outcomes of adults with restrictive cardiomyopathy after heart transplantation J Heart Lung Transplant. 2012 Dec; 31(12):1269-75. . View in PubMed
• Assessment of myocardial viability: review of the clinical significance Rev Cardiovasc Med. 2008; 9(4):225-31. . View in PubMed

• Shaddy, Robert
• Kim, Gene
• Barr, Mark